The aryloxyalkanoate dioxygenase-12 (AAD-12) protein is expressed in genetically modified soybean events DAS-68416-4 and DAS-444Ø6-6. Expression of the AAD-12 protein in soybeans confers tolerance to the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) providing an additional herbicide choice to farmers. This enzyme acts by catalyzing the degradation of 2,4-D into herbicidally inactive metabolites. To meet evolving interpretation of regulations in the European Union, three separate 28-day repeat-dose oral mouse studies were conducted at increasing doses of up to 1100 mg AAD-12 protein/kg bw/day. No treatment-related effects were seen in any of these three studies.
Introduction
High-dose acute-oral rodent toxicity studies are required globally (with the exception of the European Union) for newly expressed proteins in genetically modified (GM) crops. This requirement is based on the knowledge that toxic proteins act acutely (Delaney et al., 2008; Sjoblad et al., 1992) , and even proteins that can cause chronic effects at low doses, such as kidney bean lectin, are toxic acutely at high doses (Almeida et al., 1991; Noah et al., 1980) . However, the European Commission uniquely requires a 28-day repeat-dose rodent study instead of an acute study to support the safety assessment of GM crops (EC, 2013) . The AAD-12 (aryloxyalkanoate dioxygenase-12) enzyme is expressed in two GM soybean events ) conferring tolerance to the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) (Griffin et al., 2013; Wright et al., 2010) . AAD-12 degrades and inactivates 2,4-D and has good substrate specificity (Griffin et al., 2013) . Three separate 28-day repeat-dose mouse studies were conducted with the AAD-12 protein to meet evolving EFSA requirements. An initial study was conducted at doses up to 47 mg AAD-12 protein/kg bw/day (mg/kg/day) and a second study was conducted at doses up to 142 mg/kg/day (based on slightly different AAD-12 expression levels in the DAS-68416-4 and DAS-444Ø6-6 soybean events and different estimates of soybean consumption by humans) to achieve a targeted high dose in both studies of 1000-fold over the worst-case daily dietary exposure in humans. A third study was conducted at a hazard, limit test dose of > 1000 mg/kg/day to meet the most current interpretation of the European regulations by EFSA. Here we report the results of these three 28-day repeat-dose mouse toxicity studies with the AAD-12 protein.
Methods and materials

Doses
In the first (#091024) and second (#151062) study, mice were dosed with the AAD-12 protein at 0, 0.47, 4.7, or 47 mg/kg/day and 0, 1.42, 14.2, or 142 mg/kg/day, respectively. In the first study, AAD-12 protein was administered through the diet, while in the second, it was administered via oral gavage. The high doses in both studies were chosen to achieve at least 1000-fold margin of safety over a worst-case human exposure to soybean grain based on different AAD-12 expression estimates in the two GM soybean events and different estimates of human consumption of soybeans [GEMS Cluster Diet data: http://www. who.int/foodsafety/chem/gems/en/index1.html for soybeans (+VD541: immature seeds, dry seeds, oil; and EFSA Comprehensive European Food Consumption Database, Food consumption data relevant to applications for GMOs, Product Category: Soybean (and derived products)]. Based on the available AAD-12 protein level observed in soybean grain, and 100% consumption of AAD-12 expressing grain in the diet, worst-case human exposure was estimated at 47 and 142 μg/ kg/day in the first and second study, respectively (EFSA, 2017) . It is noteworthy that the dose selection was based on expression levels in raw grain and did not consider that the AAD-12 protein is degraded by https://doi.org/10.1016/j.yrtph.2017.12.012 Received 25 October 2017; Received in revised form 13 December 2017; Accepted 15 December 2017 the processing of soybean to inactivate endogenous antinutrients so that it is safe for consumption by monogastric animals such as humans (Papineni et al., 2017) . AAD-12 protein is below the detection limit in toasted soybean meal and oil. A third oral gavage study (#161005) was conducted at a hazard-limit test dose of 1100 mg/kg/day. Study designs used for these three studies are summarized in Table 1 .
Dosing
Lyophilized purified AAD-12 protein produced heterologously in Pseudomonas fluorescens was used to dose the mice (Griffin et al., 2013) . In the first study, a concentrated test-material feed mixture (i.e., the premix which contained the AAD-12 protein at a target concentration level) was formulated by adding necessary amounts of the AAD-12 protein to pre-chilled rodent diet (Certified Rodent LabDiet #5002 from PMI Nutrition International, St. Louis, MO). Dilutions of the premix to achieve targeted doses of AAD-12 protein were calculated based on known concentrations of AAD-12 protein in the premix, mean body weights, and feed consumption as previously described (Stagg et al., 2012) . Control and test diets were stored at −20°C. Daily aliquots of the diets were thawed and given to the mice. All dosing suspensions were prepared by mixing the test material (AAD-12 protein) in 0.5% aqueous methylcellulose at concentrations of 0.24, 2.37, or 23.67 mg/ mL and administered at a dose volume of 6 mL/kg body weight to achieve the targeted dose levels in the second study and at a concentration of 110 mg/mL and administered at a dose volume of 10 mL/ kg body weight in the third study. Dose suspensions were corrected for purity. In addition to the zero dose (vehicle control), bovine serum albumin (BSA), was included at a concentration that was equivalent to the high dose in the first and third study as a non-specific protein control group.
The concentrations of the AAD-12 Protein and BSA in 0.5% aqueous methylcellulose from the respective dose suspensions of the limit dose study (third study) were analyzed from the first mix, from a mix prepared near the middle, and from a mix prepared towards the end of the study. The analyses were conducted using amino acid analysis (AAA) method. The average recoveries for AAD-12 Protein and BSA in 0.5% aqueous methylcellulose were determined to be 71.7% and 73.2%, respectively based on nominal dosing suspensions at 110 mg/mL. The average recovery of these proteins (AAD-12 Protein and BSA) was within the acceptable experimental variation of 70-120% (Codex Alimentarius Commission, 2010).
Animals
Five, ten, and eleven, 7-8 week old, Crl CD1 (ICR) mice (Charles River Laboratories: Portage, MI or Raleigh, NC)/sex/dose were included in the first, second, and third study, respectively. During the one week acclimation period, each animal was evaluated by a laboratory veterinarian to determine the general health status and acceptability for study purposes. Before administration of test material began, animals were stratified by body weight and randomly assigned to a treatment group. Animals were caged individually at 20-26°C, 30-70% RH, 10-15 air changes per hour, and 12:12 light/dark photoperiod. Feed (LabDiet Certified Rodent Diet #5002) and water were provided ad libitum. In accordance with the U.S. Department of Agriculture Animal Welfare Regulations, 9 CFR, Subchapter A, Parts 1-4, the Animal Care and Use Activities required for conduct of these studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC).
In-life observations
Daily cage-side observations were made to monitor general health in all three studies. Clinical observations were conducted approximately 1 h post-dosing (gavage studies) each day in the second and third studies which included careful evaluation of abnormalities in the eyes, urine, feces, gastrointestinal tract, extremities, movement, posture, reproductive system, respiration, skin/hair-coat, and mucus membranes, as well as an assessment of general behavior, injuries, or palpable mass/swellings. Weekly detailed clinical observations, which included cage-side, hand held, and open field observations, were conducted on all animals in all three studies. The eyes of all animals were examined by a veterinarian pre-exposure and prior to the scheduled necropsy using indirect ophthalmoscopy. Eyes were also examined by a prosector during the necropsy using a moistened glass slide pressed to the cornea. All mice were weighed on test days 1, 2, 3, 4, 8, 15, 22, and 29. Body weight gains were calculated relative to test day 1. Feed consumption was determined at regular intervals in all three studies.
Clinical pathology
Blood was collected from the orbital sinus of non-fasted mice following anesthesia with Isoflurane/O 2 at the scheduled necropsy. Hematology and clinical chemistry analyses were conducted on five to six mice/sex/group. Analyses included hematocrit, hemoglobin, red blood cell count, total white blood cell count, differential white blood cell count, platelet count, reticulocyte count, and red blood cell indices as previously described (Stagg et al., 2012) . In addition, for the second and third study, blood samples were also collected in sodium citrate tubes from five mice/sex/dose for coagulation assay (prothrombin time). These samples were centrifuged; plasma was collected, and then assayed using an ACL9000 Analyzer (Instrumentation Laboratory, Bedford, Massachusetts). Practical limitations in obtaining sufficient quantities of blood from mice warranted hematology and clinical chemistry analyses to be conducted on five to six mice/sex/group and coagulation (prothrombin time) to be conducted on the remaining five animals in each group. Serum clinical chemistry parameters included the assessment of enzyme activities of alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, and gamma glutamyl transpeptidase, and concentrations of albumin, albumin/globulin ratio, cholesterol, creatinine, electrolytes (calcium, phosphorus, sodium, potassium, and chloride), globulin, glucose, total bile acids, total bilirubin, total protein, triglycerides, and urea nitrogen as previously described (Stagg et al., 2012 ).
Anatomic pathology
A complete necropsy was conducted on all animals by a trained team led by a veterinary pathologist. The necropsy included examination of the external tissues and all orifices. Visceral tissues were dissected from the carcass, examined, and selected tissues were incised. The nasal cavity was flushed via the nasopharyngeal duct and the lungs were distended to an approximately normal inspiratory volume with neutral, phosphate-buffered 10% formalin using a hand-held syringe and blunt needle. The brain, liver, kidney, heart, adrenals, testes, epididymides, prostate + seminal vesicles with coagulating gland and fluids, prostate, thymus, and spleen, were trimmed and weighed immediately. Ratios of organ to terminal body weight were calculated. A standard set of tissues in accordance with The Organisation for Economic Co-operation and Development (OECD) 407 test guideline was preserved in 10% neutral phosphate-buffered 10% formalin. Testes and epididymides were preserved in Bouin's fixative (OECD, 2008) . Sections from preserved tissues were processed by standard histologic procedures from the control groups and high-dose groups and histopathologic findings were graded as previously described (Stagg et al., 2012) .
Data analysis
For the first and the third study wherein an additional control group was used, i.e., BSA control group, the untreated control group (vehicle control) was first compared with the BSA-treated control group to determine the effects of increased protein intake. Because the AAD-12 protein treated groups had higher protein intake as compared with the untreated controls, it was necessary to compare them with a control group that was handled in a similar manner, i.e., the group that was given equivalent amounts of additional protein (BSA control). Therefore, in the first and third studies, the AAD-12 protein treated groups were statistically compared only with the BSA protein control following the analyses listed below. No BSA control group was used for the second study and hence, the AAD-12 protein treated groups were statistically compared with the untreated vehicle controls.
Bartlett's test (alpha = 0.01) was used to evaluate homogeneity of variance, and where significant deviations were detected, the commonlog, the inverse, and the square-root transformations were evaluated sequentially to correct the deviation. In-life body weights, feed consumption, terminal body weights, organ weights (absolute and relative, excluding prostate with seminal vesicles and coagulating glands with fluids, prostate, epididymides, and testes), hematological parameters (excluding red blood cell indices and absolute and differential white blood cell counts), and clinical chemistry (excluding globulin and albumin/globulin ratio) were evaluated using a two-way ANOVA with the factors sex and dose. If a significant (alpha < 0.05) sex-by-dose interaction was detected, a one-way ANOVA was conducted for each sex. If an overall treatment effect was detected (alpha < 0.05), a Dunnett's test was used to detect statistically significant differences between treatment and control groups (alpha < 0.05). For sex-specific organ weights, a one-way ANOVA was used within each sex group.
In addition, body weights, feed consumption, organ weights, clinical chemistry data, coagulation, and appropriate hematological data were tested for homogeneity of variance using Bartlett's test (alpha = 0.01) for each sex separately and transformed, where appropriate, as indicated earlier. Data analysis was performed by a one-way ANOVA with dose group in the model. When the overall treatment effect was found significant (alpha = 0.05), Dunnett's test (alpha = 0.05) was used to test the significance of treatment groups from the control group. Statistical outliers were identified with Grubbs' test (alpha = 0.02).
Results
Rationale
Three separate 28-day repeat-dose mouse toxicology studies were conducted with the AAD-12 protein expressed in event DAS-68416-4 and DAS-444Ø6-6 soybean. Studies included increasing doses to meet evolving interpretation of recommendations and guidance from EFSA. The two initial studies included doses based on 1000-fold margins of human exposure while the third study was conducted at a hazard-limit test dose of 1100 mg/kg/day. Because of the much higher dose included in the third study, discussion in this paper is focused on this third study. Data for the first two studies are not shown.
Survival and in-life observations
There were no treatment-related mortalities or clinical observations in animals dosed with the AAD-12 protein in any of the three studies.
Body weights, weight gain, and feed consumption
There were no statistical or treatment-related differences in body weight or body weight gain in males or females dosed with the AAD-12 protein up to 1100 mg/kg/day compared with the respective control groups in any of the three studies. Mean body weight gains of males administered 1100 mg/kg/day in the third study were slightly lower than the control group throughout the study, which was largely attributed to a single animal that only had 0.5 g body weight gain over the duration of the study (Table 2, Figs. 1 and 2) . Histopathological examination following necropsy of this animal revealed chronic active inflammation of the adventitia around the esophagus, chronic active inflammation of the mediastinal tissue, and focal degeneration with regeneration of the esophageal musculature consistent with inadvertent esophageal trauma from the repeated oral gavage procedure. The decreased body weight gain of this animal was attributed to mechanical trauma associated with the gavage procedure.
There were no treatment-related differences in mean feed consumption for males or females between the groups dosed with the AAD- 12 protein and the control groups in any of the three studies. Mean feed consumption for animals in the group administered 1100 mg/kg/day of the AAD-12 protein in the third study was statistically lower when compared with the BSA control group on test days 1-2 for males, test days 2-3 for sexes combined, and test days 22-29 for males (Table 3, Figs. 3 and 4). These differences were considered spurious and unrelated to treatment due to their transient nature, lack of body-weight effects, and minimal difference from the vehicle or BSA-control groups.
Clinical pathology
There were no treatment-related differences in any hematological parameter for males or females in the groups dosed with the AAD-12 protein compared with the control groups in any of the three studies. Statistically identified differences were noted in the third study between the group administered 1100 mg/kg/day of the AAD-12 protein compared with the BSA control group for some hematology parameters (Table 4) . White blood cell counts for males, and reticulocyte counts for females, administered the AAD-12 protein were statistically identified when sexes were analyzed separately but not when sexes were combined. The mean white blood cell count of males administered 1100 mg/kg/day of AAD-12 protein (6.26 × 10 3 /μL) was higher than the BSA control group (4.57 × 10 3 /μL) largely due to two animals, one with an abscess in the neck region and a granulomatous inflammation around the esophagus, and the other animal with a chronic active inflammation of the mediastinal tissue. The changes in these two individual animals were attributed to inadvertent trauma associated with the repeated oral gavage procedure. Moreover, these changes were within historical ranges for past 28-day oral repeat-dose studies conducted in the laboratory (3.06-7.51 × 10 3 /μL) ( Table 4 ). The mean reticulocyte count of females administered 1100 mg/kg/day of the AAD-12 protein (303.9 × 10 9 /L) was slightly lower compared with the BSA control group (367.2 × 10 9 /μL); however, this was interpreted to be unrelated to the AAD-12 protein treatment because of close proximity to the vehicle control group (315.7 × 10 9 /μL) and consistency with the historical control range of the laboratory (294.5-533.3 × 10 9 / μL) ( Table 4 ). The mean platelet count for males administered 1100 mg/kg/day of the AAD-12 protein was slightly but statistically higher (1555 × 10 3 /μL) compared with the BSA control group (1321 × 10 3 /μL). The higher mean platelet count was partially attributed to secondary inflammation in three individual animals, one with a neck abscess, a second with inflammation of mediastinal tissue, and a third with a focal fracture of the sternum (all of which were attributed to either the oral gavage procedure and/or inadvertent gavage induced trauma). Furthermore, histopathological evaluation of bone marrow sections of males in the AAD-12 group did not reveal any treatmentrelated correlate for the higher platelet count such as increased numbers of megakaryocytes. Finally, mean platelet counts for the females administered the AAD-12 protein were not significantly different from the corresponding BSA control group. There were no statistically significant or treatment-related differences in prothrombin time for males or females administered the AAD-12 protein compared with controls in any of the three studies. There were no treatment-related differences in any serum clinical chemistry parameter for males or females for the AAD-12 groups compared with the control groups in any of the three studies. The mean serum calcium level in the males and females administered 1100 mg/ kg/day of the AAD-12 protein as compared with the BSA control group was statistically higher when the sexes were analyzed together, but not when the sexes were analyzed separately (Table 5 ). The minimal increase seen for the AAD-12 group males (9.7 mg/dL) and females (9.5 mg/dL) compared with the BSA control group males (9.5 mg/dL) and females (9.3 mg/dL) was consistent with historical control ranges for males (9.0-10.4 mg/dL) and females (9.4-10.5 mg/dL) within the laboratory, and was interpreted as normal biological variability unassociated with treatment (Table 5) .
Organ weights, gross pathology, and histopathology
There were no treatment-related differences in organ weights in any of the three studies. Only one organ weight was identified as significantly different for the AAD-12 group in the third study. Males administered 1100 mg/kg/day of the AAD-12 protein had statistically lower epididymis weights (0.085 g) compared with the BSA control group (0.092 g); however, the observed value was similar to the vehicle control group (0.087 g) and was within the historical range for the laboratory (0.080-0.103 g) (Table 6 ). Moreover, there were no treatmentrelated histopathological changes in the epididymis in any of the males administered 1100 mg/kg/day of the AAD-12 protein, and therefore, the statistically identified difference was interpreted as spurious and not treatment related. There were no treatment-related gross pathologic or microscopic observations attributed to the ingestion of AAD-12 protein in the male or female mice in any of the three studies (data not shown).
Discussion
Proteins are natural part of human and animal diets and are known to undergo rapid enzymatic degradation into individual amino acids and small peptides in the gastrointestinal tract that are eventually absorbed systemically to support nutritional needs to the body. There are number of physical and biological barriers in mammals that restrict systemic absorption of intact proteins after oral consumption (Gardner, 1988; Kier and Petrick, 2008; Lodish et al., 2004) . Unsuccessful attempts at the use of orally administered proteins for therapeutic purposes exemplify the effectiveness of these natural barriers (Goldberg and Gomez-Orellana, 2003; Hamman et al., 2005; Shah et al., 2002) . Owing to their sensitivity to digestion and negligible absorption potential, oral consumption of intact proteins is generally not associated with any toxic effects (Sjoblad et al., 1992) .
Food and feed safety for newly expressed proteins is determined from the weight of evidence (OECD, 1993) . While no risk was identified for the AAD-12 protein based on its amino acid similarity to other proteins, its known enzymatic mode of action and substrate specificity, its lability in the presence of digestive enzymes and heat, its low abundance in raw soybean grain, and its absence in processed soy (Papineni et al., 2017; Schafer et al., 2016) , high-dose oral toxicity studies are required by regulatory agencies that assess the risk of GM crops. Acute oral toxicity studies in mice with the AAD-12 protein at doses up to 5000 mg/kg have demonstrated no adverse effects (unpublished). To meet EU Commission requirements and evolving interpretation of regulations, three separate 28-day repeat-dose oral toxicity studies were conducted at doses up to 1100 mg/kg/day. The first two studies were conducted at dose levels that are at least 1000-fold over worst case human exposure levels while the third study was conducted above the limit dose of 1100 mg/kg/day. Soybeans are usually toasted to reduce the levels of anti-nutritional factors and make it safe for human consumption. AAD-12 protein expressed in GM soybeans also gets denatured during heat processing. It is important to note that the dose levels for the first two studies were based on expression levels in raw grain and exposure estimates that are very conservative and an over-prediction of actual human dietary exposure to the protein. It was assumed that all the soybeans consumed will have AAD-12 expressed although soybeans are blended commodity and the estimates also did not account for protein denaturation during heat processing and cooking of soybeans. Thus, the dose levels tested in these 28-day studies are several orders of magnitude higher (> 1000 fold) than actual human dietary exposures. In conclusion, no treatment-related effects were observed in any of these three studies confirming the initial conclusion of lack of toxicity with AAD-12.
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